Question: What are the effects and harms associated with bodyweight-supported (BWS) gait training in adults with stroke according to measures of mobility, health-related quality of life (HRQoL), and adverse events?Design: Systematic review and meta-analysis of randomised controlled trials.Participants: Adults with stroke.Intervention: BWS gait training compared to any type of other intervention.Outcome measures: Gait function, walking speed, walking capacity, gait pathology, HRQoL, withdrawals, adverse events, serious adverse events.Results: A total of 102 studies (5,290 participants) were identified for inclusion. Compared with control conditions, BWS gait training was favoured for gait function (2.39 units out of 24 on the Dynamic Gait Index [95% CI, 1.40; 3.32]), walking speed (0.27 m/s on the 10-meter walk test [95% CI, 0.17; 0.37]), walking capacity (29.7 meters on the 6-minute walk test [95% CI, 9.9; 48.5]), gait pathology (4.99 degrees out of 100 on the Gait Profile Score [95% CI, 3.08; 6.86]), and HRQoL (3.92 units out of 100 on Short Form 36 Physical Component [95% CI, 1.07; 6.68]). No adverse effects related to BWS were identified.Conclusion: BWS gait training appears to be safe and produce positive effects on measures of mobility and HRQoL in adults with stroke. The certainty of evidence was low to very low. Subgroup analyses indicated that the magnitude of the effect depends on the type of unloading mechanism used when employing BWS.Trial registration: PROSPERO (CRD42021282642)

Question: What are the effects and harms associated with bodyweight-supported (BWS) gait training in adults with acquired and congenital brain injuries (ABI and CBI) according to measures of mobility, health-related quality of life (HRQoL), and adverse events?Design: Systematic review and meta-analysis of randomised controlled trials.Participants: Adults with ABI and CBI.Intervention: BWS gait training compared to any type of other intervention.Outcome measures: Gait function, walking speed, walking capacity, gait pathology, HRQoL, withdrawals, adverse events, serious adverse events.Results: A total of 99 studies (5,150 participants) were identified for inclusion. Compared with control conditions, BWS gait training improved gait function (2.28 units [0–24 point scale] on the Dynamic Gait Index [95% CI, 1.30, 3.22]), walking speed (0.27 m/s on the 10-meter walk test [95% CI, 0.17, 0.37]), walking capacity (27.71 meters on the 6-minute walk test [95% CI, 8.91, 48.51]), gait pathology (4.99 degrees [0–100 degree scale] on the Gait Profile Score [95% CI, 3.08, 6.86]), and HRQoL (3.74 units [0–100 unit scale] on Short Form 36 Physical Component [95% CI, 0.80, 6.68]). No adverse effects related to BWS were identified.Conclusion: BWS gait training appears to be safe and has a positive effect on measures of mobility and HRQoL in adults with nonprogressive ABI and CBI. The certainty of evidence was low to very low. Subgroup analyses indicated that the magnitude of the effect depends on the type of unloading mechanism used when employing BWS.Trial registration: PROSPERO (CRD42021282642)

Question: What are the effects and harms associated with bodyweight-supported (BWS) gait training in adults with acquired and congenital brain injuries (ABI and CBI) according to measures of mobility, health-related quality of life (HRQoL), and adverse events?Design: Systematic review and meta-analysis of randomised controlled trials.Participants: Adults with ABI and CBI.Intervention: BWS gait training compared to any type of other intervention.Outcome measures: Gait function, walking speed, walking capacity, gait pathology, HRQoL, withdrawals, adverse events, serious adverse events.Results: A total of 99 studies (5,150 participants) were identified for inclusion. Compared with control conditions, BWS gait training improved gait function (2.28 units [0–24 point scale] on the Dynamic Gait Index [95% CI, 1.30, 3.22]), walking speed (0.27 m/s on the 10-meter walk test [95% CI, 0.17, 0.37]), walking capacity (27.71 meters on the 6-minute walk test [95% CI, 8.91, 48.51]), gait pathology (4.99 degrees [0–100 degree scale] on the Gait Profile Score [95% CI, 3.08, 6.86]), and HRQoL (3.74 units [0–100 unit scale] on Short Form 36 Physical Component [95% CI, 0.80, 6.68]). No adverse effects related to BWS were identified.Conclusion: BWS gait training appears to be safe and has a positive effect on measures of mobility and HRQoL in adults with nonprogressive ABI and CBI. The certainty of evidence was low to very low. Subgroup analyses indicated that the magnitude of the effect depends on the type of unloading mechanism used when employing BWS.Trial registration: PROSPERO (CRD42021282642)

Question: What are the effects and harms associated with bodyweight-supported (BWS) gait training in adults with acquired and congenital brain injuries (ABI and CBI) according to measures of mobility, health-related quality of life (HRQoL), and adverse events?Design: Systematic review and meta-analysis of randomised controlled trials.Participants: Adults with ABI and CBI.Intervention: BWS gait training compared to any type of other intervention.Outcome measures: Gait function, walking speed, walking capacity, gait pathology, HRQoL, withdrawals, adverse events, serious adverse events.Results: A total of 99 studies (5,150 participants) were identified for inclusion. Compared with control conditions, BWS gait training improved gait function (2.28 units [0–24 point scale] on the Dynamic Gait Index [95% CI, 1.30, 3.22]), walking speed (0.27 m/s on the 10-meter walk test [95% CI, 0.17, 0.37]), walking capacity (27.71 meters on the 6-minute walk test [95% CI, 8.91, 48.51]), gait pathology (4.99 degrees [0–100 degree scale] on the Gait Profile Score [95% CI, 3.08, 6.86]), and HRQoL (3.74 units [0–100 unit scale] on Short Form 36 Physical Component [95% CI, 0.80, 6.68]). No adverse effects related to BWS were identified.Conclusion: BWS gait training appears to be safe and has a positive effect on measures of mobility and HRQoL in adults with nonprogressive ABI and CBI. The certainty of evidence was low to very low. Subgroup analyses indicated that the magnitude of the effect depends on the type of unloading mechanism used when employing BWS.Trial registration: PROSPERO (CRD42021282642)

Genes predicted in the scaffolds harboring the significant SNPs. (XLSX 14Â kb)

Genes predicted in the scaffolds harboring the significant SNPs. (XLSX 14Â kb)